New Drug Candidates Hold Tremendous Promise for European HIV Drugs Market
News Apr 17, 2013
The anticipated launch of drugs currently in the pipeline, together with the introduction of oral combination pills, are set to have a profound impact on the European HIV drugs market.
New analysis from Frost & Sullivan (http://www.lifesciences.frost.com), Analysis of the European HIV Drugs Market, finds that the market earned $5.58 billion in 2012 and estimates this to reach $9.24 billion in 2019.
The research covers the most actively used antiretroviral (ARV) therapies: nucleoside reverse transcriptase inhibitor (NRTI), protease inhibitor (PI), non-nucleoside reverse transcriptase inhibitor (NNRTI), integrase inhibitors, and other therapeutics (ARV compounds like CCR5 receptor antagonists, fusion inhibitors, maturation inhibitors, attachment inhibitors and PK boosters).
“In addition to popularly existing therapies like NRTI, NNRTI, PI and integrase inhibitors, new drug candidates over the last decade have spurred the HIV drugs market,” notes Frost & Sullivan Healthcare Research Analyst Deepika Pramod Chopda.
Chopda continued, “The development of new candidates, derived from the less commonly used types of ARV therapies like PK boosters, maturation inhibitors, and attachment inhibitors, is driving the overall market.”
With technically advanced features like easy consumption and higher adherence to combination therapy, these candidates assist highly active antiretroviral therapies (HAART), which are a combination of three or four types of ARV therapies.
Their value-added features and improved efficacy are expected to boost the prospects of less common drug types.
The introduction of one-pill-daily combination drugs will also be a key factor in market development. A reduction in the number of drugs that need to be consumed directly reduces patient expenditure levels. Other advantages include convenience and ease of consumption.
This trend is poised to have a steady impact on the growth of the HIV drugs market. It is also likely to shift the focus from syringes, as a source of drug administration, to directly consumable pills.
A major restraint to market expansion remains poor compliance rates due to the absence of established treatment procedures. This can be offset by improving access to disease awareness campaigns, treatment guidelines, counselling sessions and targeted diagnostics from health governing bodies.
“Awareness building efforts related to HIV prevention among high-risk groups is increasing,” concludes Chopda. “Better understanding about the need to practice safe-sex, use sterilized needles and conduct blood transfusion in a sterile environment, are also helping market prospects.”
Blood Cancers are Outsmarting the Immune System, But How?News
Researchers have discovered how some of the blood cancers known as myeloproliferative neoplasms (MPNs) evade the immune system.READ MORE
Can You Eat Cells? Computer Model Predicts Organisms that Use PhagocytosisNews
A computer model developed by Museum researchers may provide new insight into the origins of phagocytosis, the process by which single-celled organisms “eat” other cells as a means of absorbing nutrients or eliminating pathogens.READ MORE
‘Lipid Asymmetry’ Plays Key Role in Activating Immune CellsNews
Regulating the lipid and physical asymmetry of a cell’s membrane is critical to immune cell function, and researchers have now shown that by preventing loss of membrane asymmetry it’s possible to control the immune response.READ MORE
Comments | 0 ADD COMMENT
World Advanced Therapies & Regenerative Medicine Congress
May 16 - May 18, 2018